Zevra Therapeutics has won Food and Drug Administration approval of Miplyffa for Niemann-Pick disease type C, making it the first drug cleared in the U.S. for the rare neurodegenerative disorder.
An Endodontic mode has been created within the Navident EVO system, reportedly improving the ability of the clinician to effectively detect, diagnose, and plan treatment prior to dynamic navigation.